Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Karin A. van Schie; Simone Kruithof; Pauline A. van Schouwenburg; Anke Vennegoor; Joep Killestein; Gertjan Wolbink; Theo Rispens

doi:10.1016/j.jaci.2016.09.014

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Karin A. van Schie, Simone Kruithof, Pauline A. van Schouwenburg, Anke Vennegoor, Joep Killestein, Gertjan Wolbink, Theo Rispens

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1035-1037.e6
Journal	Journal of Allergy and Clinical Immunology
Volume	139
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2016.09.014
Publication status	Published - 1 Mar 2017

Access to Document

10.1016/j.jaci.2016.09.014

Cite this

van Schie, K. A., Kruithof, S., van Schouwenburg, P. A., Vennegoor, A., Killestein, J., Wolbink, G., & Rispens, T. (2017). Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. Journal of Allergy and Clinical Immunology, 139(3), 1035-1037.e6. https://doi.org/10.1016/j.jaci.2016.09.014

@article{310b0059654749eeabe448f23f62ed66,

title = "Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site",

author = "{van Schie}, {Karin A.} and Simone Kruithof and {van Schouwenburg}, {Pauline A.} and Anke Vennegoor and Joep Killestein and Gertjan Wolbink and Theo Rispens",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.jaci.2016.09.014",

language = "English",

volume = "139",

pages = "1035--1037.e6",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

van Schie, KA, Kruithof, S, van Schouwenburg, PA, Vennegoor, A , Killestein, J, Wolbink, G & Rispens, T 2017, 'Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site', Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. 1035-1037.e6. https://doi.org/10.1016/j.jaci.2016.09.014

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies : The immune response to antibody therapeutics preferentially targets the antigen-binding site. / van Schie, Karin A.; Kruithof, Simone; van Schouwenburg, Pauline A. et al.

In: Journal of Allergy and Clinical Immunology, Vol. 139, No. 3, 01.03.2017, p. 1035-1037.e6.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies

T2 - The immune response to antibody therapeutics preferentially targets the antigen-binding site

AU - van Schie, Karin A.

AU - Kruithof, Simone

AU - van Schouwenburg, Pauline A.

AU - Vennegoor, Anke

AU - Killestein, Joep

AU - Wolbink, Gertjan

AU - Rispens, Theo

PY - 2017/3/1

Y1 - 2017/3/1

UR - http://www.scopus.com/inward/record.url?scp=85006263551&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.09.014

DO - 10.1016/j.jaci.2016.09.014

M3 - Article

C2 - 27717666

AN - SCOPUS:85006263551

VL - 139

SP - 1035-1037.e6

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A , Killestein J, Wolbink G et al. Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. Journal of Allergy and Clinical Immunology. 2017 Mar 1;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Access to Document

Other files and links

Cite this